Journal Article Review Ahead of print
PubMed: 41317503 DOI: 10.1016/j.canrad.2025.104769
Radiotherapy of bone metastases: 2025 update.
Cancer Radiother 29(7-8):104769
Authors: Nicolas Martz, Jean Christophe Faivre, Guillaume Beldjoudi, Antoine Arnaud, Jérôme Chamois, Stéphane Supiot, Maximilien Rogé, Sébastien Thureau
Affiliations
- Département de radiothérapie, Institut de cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.
- Département de physique médicale, centre Léon-Bérard, Lyon, France.
- Département de radiothérapie, institut Sainte-Catherine, Avignon, France.
- Département de radiothérapie, centre hospitalier privé Saint-Grégoire, Rennes, France.
- Département de radiothérapie, Institut de cancérologie de l'Ouest, Saint-Herblain, France.
- Département de radiothérapie et de physique médicale, centre Henri-Becquerel, Quantif-AIMS, Rouen, France.
- Département de radiothérapie et de physique médicale, centre Henri-Becquerel, Quantif-AIMS, Rouen, France.
Abstract
We present the updated recommendations of the Société française de radiothérapie oncologique (the French society for radiation oncology) regarding the indications and technical modalities of radiotherapy for bone metastases. This treatment is commonly used in the management of patients with cancer. In most cases, it involves relatively simple radiotherapy technique with proven efficacy in reducing pain or managing spinal cord compression. More complex treatments using stereotactic conditions can be proposed for patients with painful bone metastases, oligometastatic disease, or in case of reirradiation. In this context, increased vigilance must be given to the risks of spinal cord toxicity.
MeSH
Radiotherapy, Spinal Cord, Pain, Neoplasm Metastasis, Therapeutics, Spine